Orexo's patent win for ZUBSOLV® appealed Jul 24, 2023 02:24AM
Orexo announces new US patent for ZUBSOLV® Dec 30, 2020 02:09AM
Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020 Nov 4, 2020 05:23AM
Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders Sep 1, 2020 08:22AM
Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US Aug 10, 2020 02:09AM


Jul 2, 2020 02:34AM Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance
Jun 30, 2020 02:28AM Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal
Jun 17, 2020 08:17AM Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder
May 18, 2020 08:17AM Orexo and Lyfebulb Partner During Unprecedented Times to Help Those Struggling With Alcohol and Opioid Use Disorders
May 11, 2020 02:24AM Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
Apr 6, 2020 02:12AM Orexo Ends Share Buy-back Program
Mar 26, 2020 09:15AM Orexo Publishes the Annual Report for 2019
Mar 17, 2020 03:34AM Orexo Presents Sales Potential of the Pharmaceutical Pipeline and Digital Therapies During the Capital Markets Day
Mar 6, 2020 02:26AM Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US
Feb 19, 2020 03:05AM Invitation - Orexo Capital Markets Day, Stockholm, Sweden, March 17
Dec 2, 2019 02:17AM Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health
Nov 8, 2019 07:14AM Orexo to Present at Jefferies 2019 Healthcare Conference
Aug 20, 2019 02:09AM Orexo Signs Partnership Agreement With GAIA to Develop and Commercialize a new Digital Therapy for the Treatment of Opioid Use Disorder
Oct 31, 2017 04:00AM Orexo Issues Bonds of SEK 325 Million and Confirms Fulfilment of Condition Under Notice of Early Redemption
Oct 27, 2017 03:37AM Orexo Announces Conditional Total Redemption of its Senior Unsecured Bonds
Aug 2, 2017 03:27AM Orexo: Zubsolv® Gains Preferred Position on CVS Caremark 2018 Formulary
Jun 2, 2017 02:30AM Orexo Receives USD 2.5 Million Milestone Payment From AstraZeneca as OX-CLI Advances Into Clinical Trials